Equity Profile

DYN

Dyne Therapeutics, Inc.

Health CareBiotechnology$3.9B

Jul27Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, Dyne is working on treatments that harness the power of gene therapy, which is a major theme in modern medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations by 1.35%. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are keenly awaiting Dyne's earnings report, especially given the company's recent performance. The lack of analyst estimates adds uncertainty to market expectations.

Bull Case

If Dyne can show strong revenue growth and continued improvement in EPS, it could signal a turnaround and attract more investor interest.

Bear Case

Conversely, if the company fails to meet expectations on profitability or revenue, it could lead to a significant sell-off given the current market cap.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Dyne provide for its ongoing projects?

Revenue figures will be critical in assessing the success of Dyne's product pipeline and overall market position.

How does Dyne plan to address its ongoing losses in EPS?

Understanding the company's strategy for improving profitability will be key for investors concerned about financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Dyne's therapies to gain traction in the market, especially given the recent positive surprises.

Supporting Evidence

Dyne has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Insider selling could signal confidence in the company's long-term strategy despite short-term losses.

Key Risk

If Dyne's revenue growth exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

Investors are debating whether Dyne can turn its innovative therapies into profitable products while managing its financial losses.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bullish outlook.

Bear Confirmed If

An EPS loss greater than -$0.80 would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±35.44%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$19.2M

970,528 sh

2 insiders

Net

$19.2M

Net selling

Most Active Insiders· 19 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations, history suggests a potential stock increase of around 5.96%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors assess management commentary.

Miss

A miss could lead to a decline of about 9.27%, reflecting investor disappointment and concerns over profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth from key projects.
2Updates on the timeline for product launches.
3Management's strategy for reducing EPS losses.
4Any new partnerships or collaborations that could enhance growth.
5Insights into market demand for Dyne's therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aon plc

Company Snapshot

Dyne Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DYN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-5.31%

Avg Stock Reaction

+2.20%

Last Quarter Recap

In Q1 2026, Dyne reported an EPS of -$0.73, slightly beating expectations by 1.35%. The stock reacted positively, gaining 4.83% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are keenly awaiting Dyne's earnings report, especially given the company's recent performance. The lack of analyst estimates adds uncertainty to market expectations.

Bull Case

If Dyne can show strong revenue growth and continued improvement in EPS, it could signal a turnaround and attract more investor interest.

Bear Case

Conversely, if the company fails to meet expectations on profitability or revenue, it could lead to a significant sell-off given the current market cap.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Dyne provide for its ongoing projects?

Revenue figures will be critical in assessing the success of Dyne's product pipeline and overall market position.

How does Dyne plan to address its ongoing losses in EPS?

Understanding the company's strategy for improving profitability will be key for investors concerned about financial sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Dyne's therapies to gain traction in the market, especially given the recent positive surprises.

Supporting Evidence

Dyne has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Insider selling could signal confidence in the company's long-term strategy despite short-term losses.

Key Risk

If Dyne's revenue growth exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

Investors are debating whether Dyne can turn its innovative therapies into profitable products while managing its financial losses.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bullish outlook.

Bear Confirmed If

An EPS loss greater than -$0.80 would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±35.44%

Historical Avg

±6.0%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±35.4% while DYN has averaged ±6.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.5%

Calls (4K)P/C Ratio: 1.91Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$19.2M

970,528 sh

2 insiders

Net

$19.2M

Net selling

Most Active Insiders· 19 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dyne beats expectations, history suggests a potential stock increase of around 5.96%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors assess management commentary.

Miss

A miss could lead to a decline of about 9.27%, reflecting investor disappointment and concerns over profitability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth from key projects.
2Updates on the timeline for product launches.
3Management's strategy for reducing EPS losses.
4Any new partnerships or collaborations that could enhance growth.
5Insights into market demand for Dyne's therapies.